Nanoparticles in Biotechnology, Drug Development and Drug Delivery Systems
The global market for nanoparticles in biotechnology, drug development and drug delivery should grow from $83.4 billion in 2020 to $123.6 billion by 2025, at a compound annual growth rate (CAGR) of 8.2% for the period of 2020-2025.
- 43 tables
- An overview of the global nanoparticles in biotechnology, drug development and drug delivery market
- Estimation of the market size and analyses of market trends, with data from 2019, estimates for 2020 and projection of CAGR through 2025
- Highlights of the drug development, formulation, and the development of new drug delivery systems and detailed product analyses within health and wellness subsegments
- Information on nanomedicine and biomedical nanoparticle products and coverage of the next generation vaccines
- Evaluation of current market trends, market size, market forecast, and detailed analysis of drivers, challenges, and opportunities affecting market growth
- Discussion on the role of nanotechnology in COVID-19 vaccine production, components, and methods in the vaccine design for COVID-19 and challenges for vaccine disruptions
- Assessment of various approaches for the treatment of COVID-19, and detailed description of structure and penetration of corona virus
- Details of clinical trials of nanoparticle drugs and drug delivery systems
- A look at the patents, licensing, mergers and acquisitions and market share analysis of the key companies of the industry
- Company profiles of major players including Bristol-Myers Squibb Co., GlaxoSmithKline PLC, Hofmann-La Roche Inc., Merck & Co., and Novartis AG
The scope of the report includes an overview of the global market for nanoparticles in biotechnology, drug development and drug delivery, and analyses of global market trends, using 2019 as the base year and forecasting 2020 through 2025 with compound annual growth rate (CAGR) projections.
The report includes analysis of leading and emerging drug products for each nanoparticle type. Profiles of manufacturers of leading products and their specific products are provided. This report also assesses companies poised to introduce products during the forecast period and discusses how these introductions will change the face of the competitive environment. The competitive environment is examined with a special focus on how new products will alter the quality of life of patients receiving nanoparticle-associated drugs.
Market figures are based on revenues at the manufacturer level and are projected in 2019 dollar value. Inflation is not computed into the projection figures. Trends are assessed based on projected sales for existing products, for new product introductions, expanded markets for existing products, and other factors affecting the market included in this report are forecasts by product, product category and by company.
The study is arranged to offer an overview of existing nanoparticle technology and of drug markets; it is accompanied by nanoproduct, company, geography, and mechanism of action, with forecasts broken down and covered by geographic region or country.
Patent and clinical trial information is reviewed for various candidate nanodrugs. The status of approvals of drugs in each segment by the FDA and regulatory agencies in other countries is reviewed.
Figures are reported in U.S. dollars and in each case reflect currency fluctuations within the performance of revenue change. Revenue figures do not account for variation in local currencies. All market share data presented is on a global basis unless specifically noted.
Regional analysis includes North America (U.S., Canada, Mexico), Europe (U.K., Germany, France, Spain, Italy, Rest of Europe), Asia-Pacific (China, India, Japan, and Rest of Asia-Pacific), and the Rest of the world (South America, and the Middle East and Africa).
BCC Publishing Staff comprises expert analysts who are skilled in conducting primary research, secondary research and data analysis and have decades of combined experience covering a wide range of industries, including healthcare, advanced materials and emerging technologies. Collectively, the team represents a diverse set of educational achievements with individual graduate work completed in fields such as microbiology, electrical engineering, business administration and surgery, among others.
The global market for nanoparticles in biotechnology and pharmaceuticals reached nearly $25.0 billion in 2013. This market is expected to reach $29.6 billion in 2014 and $79.8 billion in 2019, with a compound annual growth rate (CAGR) of 22.0% for the period of 2014 to 2019.
- An overview of the global market for nanoparticles in biotechnology, drug development, and drug delivery.
- Analyses of global market trends, with data from 2012 and 2013, estimates for 2014, and projections of CAGRs through 2019.
- A review of existing drug products and potential drugs in the pipelines of the major pharmaceutical players in the market.
- A look at how market growth is being driven in emerging geographies stemming from the health awareness of the growing middle class in countries such as India, China, Brazil and Russia.
- Analysis of changing market dynamics, emerging players and products, strategies for accessing emerging markets, and analysis of specific disease prevalence.
- Profiles of manufacturers of leading products and information on their specific products.
The global market for nanoparticles in biotechnology, drug development and drug delivery was valued at $17.5 billion in 2011 and should reach nearly $21.6 billion in 2012. Total market value is expected to reach $53.5 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 19.9%.